[Nick Hargrave]

https://www.londonstockexchange.com/news-article/AVCT/successful-completion-of-sixth-dose-escalation/16129402

Difficult to comprehend the potential significance of this announcement. They have confirmed efficacy with tumour volume reduction and are aiming to bring forward the Phase 2 study on the back of an accelerated Phase 1b study to run in parallel with cohort 7. The CEO notes they are “on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients”. We will looking to be adding a substantial position to the model portfolio this morning, moving to an overweight position